Xilio Therapeutics Inc.

XLO | NASDAQ

Price Alert Chart Builder DCF Calculator

$9.04

+$0.02 (+0.22%)

Sep 22, 2026, 1:13 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.22%

(1D)

Rating

Updated: Aug 22, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $59.44M

1D Range

8.94 9.16

52W Range

6.47 12.74

Valuation (TTM)

PE -5.50

PB 0.82

EV/EBITDA 3.44

Valuation (NTM)

Forward PE 1.54

Forward PEG 0.44

Price Target $98

Cash Flow

FCF Yield -103.3%

SBC Adj. FCF Yield -116.6%

SBC Impact -12.8%

Margins

Gross Margin 99.5%

Operating Margin -48.9%

FCF Margin -95.6%

Growth (CAGR)

Revenue 3Y | 5Y 113.7% | 87.9%

Dil EPS 3Y | 5Y 96.7% | 82.4%

FCF 3Y | 5Y -71.3% | 19.7%

Returns

ROA -14.2%

ROE -50.8%

ROIC -25.8%

Financial Health

Net Cash

$136.04M

Current Ratio 4.25

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX1...

Sector Healthcare

Industry Biotechnology

Employees 76

IPO Date Oct 21, 2021

Website www.xiliotx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 5, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞